Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Progenics Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenics Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Progenics Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Progenics Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Progenics Pharmaceuticals, Inc.'s pipeline products

Reason to Buy

- Evaluate Progenics Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Progenics Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenics Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Progenics Pharmaceuticals, Inc. Snapshot 5
Progenics Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Progenics Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Progenics Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Progenics Pharmaceuticals, Inc. - Pipeline Products Glance 12
Progenics Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Progenics Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Progenics Pharmaceuticals, Inc. - Drug Profiles 14
Edotreotide Labeled Yttrium 90 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
iobenguane sulfate I 131 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PSMA ADC 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MIP-1095 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Progenics Pharmaceuticals, Inc. - Pipeline Analysis 21
Progenics Pharmaceuticals, Inc. - Pipeline Products by Target 21
Progenics Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 22
Progenics Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 23
Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 24
Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates 25
Progenics Pharmaceuticals, Inc. - Dormant Projects 29
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
PSMA VRP Vaccine 30
Progenics Pharmaceuticals, Inc. - Company Statement 31
Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables

Progenics Pharmaceuticals, Inc., Key Information 5
Progenics Pharmaceuticals, Inc., Key Facts 5
Progenics Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
Progenics Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Progenics Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Progenics Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 10
Progenics Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
Progenics Pharmaceuticals, Inc. - Phase II, 2015 12
Progenics Pharmaceuticals, Inc. - Preclinical, 2015 13
Progenics Pharmaceuticals, Inc. - Pipeline by Target, 2015 21
Progenics Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 22
Progenics Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 23
Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 24
Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 25
Progenics Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 29
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 30
Progenics Pharmaceuticals, Inc., Subsidiaries 34